Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
NCT05711862 · The University of Texas Health Science Center, Houston · PHASE2 · terminated · last registry update 2025-04-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of enrollment” | – | Registry record, The University of Texas Health Science Center, Houston |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCRTR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-16Results posted on the registry: Brigham and Women's Hospital, Suvorexant + Placebo (NCT05593653)
- 2026-03-24Results posted on the registry: Baylor College of Medicine, Lemborexant 10 mg + Naltrexone (NCT05458609)
- 2026-02-04Results posted on the registry: University of California, San Francisco, Lemborexant + Placebo (NCT05344443)
- 2026-01-15Results posted on the registry: Duke University, Suvorexant 20 mg + Placebo (NCT05733286)
- 2025-12-23Results posted on the registry: Johns Hopkins University, Suvorexant (dual orexin receptor antagonist) + Placebo (NCT05546515)
- 2025-10-30Results posted on the registry: University of Maryland, Baltimore, suvorexant (or placebo) (NCT05908526)
- 2025-10-30Results posted on the registry: Ohio State University, Suvorexant (NCT05656534)
- 2025-10-27Results posted on the registry: Beth Israel Deaconess Medical Center, Suvorexant 20 mg + Placebo oral tablet (NCT04092894)
- 2025-10-01Results posted on the registry: The University of Texas Health Science Center, Houston, Suvorexant 20 mg + Suvorexant 0mg (NCT04234997)
- 2025-07-11Results posted on the registry: University of Rochester, Daridorexant 50 mg (NCT06630390)
- 2025-07-03Results posted on the registry: Eisai Co., Ltd., Lemborexant (NCT05594589)
- 2025-06-19Phase 3 first posted: Nxera Pharma Korea Co., Ltd., Daridorexant + Placebo (NCT07028697)
- 2025-06-04Results posted on the registry: Janssen Research & Development, LLC, Seltorexant + Placebo (NCT04532749)
- 2025-06-04Also stopped (terminated): Janssen Research & Development, LLC, Seltorexant + Placebo (NCT04532749)
- 2025-05-01Also stopped (withdrawn): Mayo Clinic, Suvorexant (NCT06834386)
- 2025-04-27Also stopped (terminated): Janssen Research & Development, LLC, Seltorexant + Placebo (NCT04951609)
- 2025-04-18Results posted on the registry: Idorsia Pharmaceuticals Ltd., Daridorexant + Placebo (NCT05597020)
- 2025-02-03Results posted on the registry: Theodore R. Brown, MD MPH, Suvorexant + Placebo (NCT03110315)
- 2024-12-20Results posted on the registry: Eisai Co., Ltd., Lemborexant + Placebo (NCT04549168)
- 2024-11-25Results posted on the registry: Janssen Research & Development, LLC, Seltorexant + Placebo (NCT05307692)
- 2024-11-13Results posted on the registry: Virginia Commonwealth University, Lemborexant + Placebo (NCT04818086)
- 2024-10-24Phase 3 first posted: Merck Sharp & Dohme LLC, Suvorexant + Placebo (NCT06655883)
- 2024-09-25Also stopped (terminated): Wayne State University, Suvorexant + Suvorexant Placebo (NCT04262193)
- 2024-08-20Results posted on the registry: Burdick, Daniel, M.D., Suvorexant + Placebo (NCT02729714)
- 2024-08-19Phase 3 first posted: Janssen Research & Development, LLC, Seltorexant + Placebo (NCT06559306)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision